Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

T-cell states in aortic dissection: from molecular immune profiling toward causal and translational validation.

Created on 30 Oct 2026

Authors

Xiang Ye, Yihao Wang, Yeting Li, Hao Zhu, Xia Li, Jianxiang Song

Published in

Annals of medicine. Volume 58. Issue 1. Pages 2753327. Epub Oct 29, 2026.

Abstract

Single-cell RNA sequencing and T-cell receptor profiling reveal substantial T-cell heterogeneity in aortic dissection (AD), but whether these responses contribute to vascular injury or reflect post-onset immune activation remains uncertain. This review evaluates human and experimental evidence by disease stage, tissue compartment, functional validation, T-cell specificity, and intervention timing, distinguishing descriptive profiling from evidence supporting causal and translational inference.
Human studies identify Th1/Th17-associated, CD8+ cytotoxicity-associated, and regulatory T-cell alterations, with stage-related differences in T-cell composition and clonality. Most evidence is cross-sectional and obtained after clinical onset. Antigen specificity, direct aortic-wall cytotoxicity, impaired Treg suppression, and T-cell-mediated aortic-wall injury remain unproven. Single-cell and TCR profiling identify candidate T-cell states and clonotypes for spatial and functional validation, not causal proof. Among candidate pathways, the IL-6-STAT3-IL-17 axis currently has the strongest AD-specific preclinical rationale, but existing interventions are largely non-T-cell-restricted and initiated before or during disease induction. Stronger causal attribution requires convergent human evidence, post-lesion T-cell-restricted perturbation, disease-progression endpoints, and rescue or target-engagement studies. The subacute phase after anatomical and haemodynamic stabilisation may offer a window to study persistent injury-amplifying T-cell responses, whereas early acute and perioperative immunomodulation remains unsupported.
Current evidence supports altered T-cell states after AD onset but does not establish an initiating role. Near-term priorities should be prospective biomarker validation and post-lesion mechanistic studies rather than T-cell-directed immuno-modulation during the early acute and perioperative phases. Clinical translation should await reproducible associations linked to stage-specific causal mechanisms and acceptable safety.

PMID:
42956058
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement